41 research outputs found
Methods Used in Economic Evaluations of Chronic Kidney Disease Testing — A Systematic Review
Background: The prevalence of chronic kidney disease (CKD) is high in general populations around the world. Targeted testing and screening for CKD are often conducted to help identify individuals that may benefit from treatment to ameliorate or prevent their disease progression. Aims: This systematic review examines the methods used in economic evaluations of testing and screening in CKD, with a particular focus on whether test accuracy has been considered, and how analysis has incorporated issues that may be important to the patient, such as the impact of testing on quality of life and the costs they incur. Methods: Articles that described model-based economic evaluations of patient testing interventions focused on CKD were identified through the searching of electronic databases and the hand searching of the bibliographies of the included studies. Results: The initial electronic searches identified 2,671 papers of which 21 were included in the final review. Eighteen studies focused on proteinuria, three evaluated glomerular filtration rate testing and one included both tests. The full impact of inaccurate test results was frequently not considered in economic evaluations in this setting as a societal perspective was rarely adopted. The impact of false positive tests on patients in terms of the costs incurred in re-attending for repeat testing, and the anxiety associated with a positive test was almost always overlooked. In one study where the impact of a false positive test on patient quality of life was examined in sensitivity analysis, it had a significant impact on the conclusions drawn from the model. Conclusion: Future economic evaluations of kidney function testing should examine testing and monitoring pathways from the perspective of patients, to ensure that issues that are important to patients, such as the possibility of inaccurate test results, are properly considered in the analysis
Choosing an epidemiological model structure for the economic evaluation of non-communicable disease public health interventions
Kosten-Nutzenbewertung der ACE-Hemmer-Therapie bei neu diagnostizierten Typ-2-Diabetikern in Deutschland - ein Markov-Modell
To screen or not to screen for albuminuria? Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of diabetic nephropathy in the Netherlands - A Markov Model
Sollten Kosten-Nutzen-Analysen die Kosten für Konsum- und Freizeitaktivitäten berücksichtigen? - Eine empirische Untersuchung
Das Bias-Risiko in Studien-basierten gesundheitsökonomischen Evaluationen in der Allgemeinmedizin - ein Leitfaden
Wo gesundheitsökonomische Evaluationen auf die Allgemeinmedizin treffen: Stellenwert und Entwicklung der Gesundheitsökonomie in der allgemeinmedizinischen Forschung
Gesundheitsökonomische Evaluationen in der Allgemeinmedizin: Die ECOBIAS-Checkliste als Tool zur systematichen Fehler-Analyse
Burnout and work satisfaction in general practitioners practicing in rural areas: results from the HaMEdSi study [Corrigendum]
Adarkwah CC, Schwaffertz A, Labenz J, Becker A, Hirsch O. Psychol Res Behav Manag. 2018;11:483–494.On page 493, Table S1 should read as follows: [see Corrigendum file for revised table]On page 494, the missing reference for reference 1 should read as follows:Reference1. Maslach C and Jackson SE. MBI: human services survey. Available from: https://www.mindgarden.com/314-mbi-human-servicessurvey#horizontalTab2. Accessed October 30, 2018.Read the original articleThe original article has been updated.